Cerenome (PSTV) Enterprise Value (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Enterprise Value of -$15.1 million for Q1 2026, down 53.18% year-over-year from -$32.3 million in Q1 2025, and down 70.66% quarter-over-quarter from -$8.9 million in Q4 2025.
Cerenome (PSTV) Enterprise Value (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Enterprise Value for 17 consecutive years, with -$15.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 53.18% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$15.1 million (down 53.18% YoY), while the FY2025 annual figure was -$8.9 million, down 145.59% from the prior year.
- Enterprise Value slipped to -$15.1 million in Q1 2026 per PSTV's latest filing, from -$8.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.1 million in Q1 2024 and bottomed at -$21.2 million in Q1 2022.
- Historically, Enterprise Value has averaged -$11.6 million across 5 years, with a median of -$10.9 million in 2023.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 83.21% — and 2025, when it slumped 361.94%.
- Plus Therapeutics' Enterprise Value stood at -$18.1 million in 2022, then jumped by 52.79% to -$8.6 million in 2023, then jumped by 57.84% to -$3.6 million in 2024, then tumbled by 145.59% to -$8.9 million in 2025, then slumped by 70.66% to -$15.1 million in 2026.
- Business Quant data shows PSTV's Enterprise Value at -$15.1 million in Q1 2026, -$8.9 million in Q4 2025, and -$16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 2.12 Bn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.11 Mn |
| Dec 31, 2025 | -8.86 Mn |
| Sep 30, 2025 | -16.60 Mn |
| Jun 30, 2025 | -6.88 Mn |
| Mar 31, 2025 | -9.87 Mn |
| Dec 31, 2024 | -3.61 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -8.44 Mn |
| Mar 31, 2024 | -2.14 Mn |
| Dec 31, 2023 | -8.55 Mn |
| Sep 30, 2023 | -11.01 Mn |
| Jun 30, 2023 | -10.90 Mn |
| Mar 31, 2023 | -12.72 Mn |
| Dec 31, 2022 | -18.12 Mn |
| Sep 30, 2022 | -20.27 Mn |
| Jun 30, 2022 | -18.09 Mn |
| Mar 31, 2022 | -21.24 Mn |
| Dec 31, 2021 | -18.40 Mn |
| Sep 30, 2021 | -21.28 Mn |
| Jun 30, 2021 | -17.16 Mn |